The prostate, lung, colon, and ovarian (PLCO) cancer screening trial: Status and promise

Urol Oncol. Jul-Aug 2004;22(4):358-61. doi: 10.1016/j.urolonc.2004.04.013.

Abstract

The Prostate, Lung, Cancer, and Ovarian Cancer Screening Trial is a randomized, multicenter, study evaluating whether screening for prostate, lung, colon, and ovarian cancer will reduce cancer-specific mortality. More than 155,000 participants have been identified and will be monitored through 2015. A biorepository of screened individuals and control participants has been created. Together, the data derived from the intervention and control arms and material in the biorepository provide a valuable resource to allow identification and testing of novel biomarkers for human disease.

Publication types

  • Clinical Trial
  • Multicenter Study
  • Randomized Controlled Trial

MeSH terms

  • Aged
  • Biomarkers, Tumor / analysis*
  • Colonic Neoplasms / diagnosis*
  • Colonic Neoplasms / mortality
  • Databases, Factual
  • Female
  • Humans
  • Lung Neoplasms / diagnosis*
  • Lung Neoplasms / mortality
  • Male
  • Mass Screening*
  • Middle Aged
  • Mortality / trends
  • Ovarian Neoplasms / diagnosis*
  • Ovarian Neoplasms / mortality
  • Prostatic Neoplasms / diagnosis*
  • Prostatic Neoplasms / mortality
  • Risk Factors

Substances

  • Biomarkers, Tumor